Our research further clarifies the reason for declined ZO-2 in GC tumors, especially in tumor tissues with active proliferation and invasion, meaning S100A16 induces ZO-2 ubiquitination which is responsible for the abnormal ZO-2 degradation via ubiquitin-proteasomal system (UPS). This evidence concerns the gene S100A16 and neoplasm.